Keep an eye on your patients' vision
Digital vision tests designed by ophthalmologists to track the progress of retinal diseases.
Medical innovation at the service of vision
OdySight® is a Class I medical device, CE certified in accordance with European Directive 93/42/EEC (MDD). With a commitment to the transition to the European Medical Device Regulation (MDR), OdySight® embodies innovation and compliance at the service of healthcare professionals and their patients.
The solution that optimizes the care pathway
Connected to your patients' mobile app, OdySight® allows you to track the evolution of their vision between consultations.
Early detection
Our solution helps you quickly detect changes in visual acuity or damage to the second eye, enabling you to optimize patient care in accordance with the recommendations of the Haute Autorité de Santé(French National Authority for Health).
Accessibility and autonomy
OdySight® creates a link between doctor and patient, facilitating access to care. It encourages patients to take charge of their visual health through regular follow-up at home.
Patient engagement
The app rewards your patients with points for access to fun puzzles. Visual acuity monitoring becomes fun and easy to integrate into their routine.
Currently, patients being monitored with Odysight have*:
Exudative AMD
Geographical atrophy
Drusen/MLA/DMLA intermediate
Severe myopia
Diabetic macular edema
Retinal vein occlusion
SCCR
Other causes
*Odysight internal data—July 2026
OdySight®, clinically validated
Our solution is based on solid scientific results:
- Clinical studies conducted by Tilak Healthcare (developer of OdySight®) such as TIL001, TIL002 and TIL003
- Independent studies by renowned experts such as Dr. Guigou and Dr. Kielwasser.
Tilak Healthcare is committed to the continuous evaluation and improvement of its solutions, guaranteeing that its technology always meets medical requirements.
Keep in touch with your patients
1 in 5
ophthalmologist
already offersOdySight® to its patients in France*
72 %
ophthalmologists
report a positive difference in care**.
34 000
patients
have been prescribed*
2
injections per day
The total number of injections administered following an Odysight notification in 2025*
Sources: *OdySight internal data, France, from 2018 to Q1 2026
**Final report on the OdySight® Article 51 pilot study. Quantitative survey conducted by IQVIA among 46 healthcare professionals.
Dr. Quaranta
Retinologist, Rabelais Center, Lyon
Join the 1,280 ophthalmologists* who are already using it
*OdySight internal data – 2018 through June 2026
The first remote monitoring service in ophthalmology covered by Medicare
Since December 2025,OdySight®has been the first telemonitoring service in France to be reimbursed under the PECAN program.
This “Early Coverage of a Digital Medical Device” program is an innovative pathway to market that allows for early, temporary, and transitional reimbursement prior to seeking inclusion in the general reimbursement system.
They talk about us
Contact us
If you are a healthcare professional and would like to find out more about the OdySight® solution, please contact us.